{
    "2021-08-14": [
        [
            {
                "time": "",
                "original_text": "本土Biotech后浪生猛，跨国MNC群狼环伺，传统药企如何破局创新转型？从Me-too到BIC，License-in已成首选？",
                "features": {
                    "keywords": [
                        "本土Biotech",
                        "跨国MNC",
                        "传统药企",
                        "创新转型",
                        "Me-too",
                        "BIC",
                        "License-in"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "制药行业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}